Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Lifco AB (publ) (1)
Mandate

Vinge has advised Lifco AB (publ)

February 13, 2017

Vinge has advised Lifco AB (publ) and its wholly owned subsidiary Sorb Industri AB in connection with its acquisition of Haglöf Sweden AB, a world leading supplier of professional forest inventory instruments. Lifco acquires and develops market-leading niche businesses with the potential to deliver sustainable profit growth and robust cash flows. The Group has three business areas: Dental, Demolition & Tools and Systems Solutions. The Lifco Group comprises 133 companies in 28 countries. In 2015 the Group reported EBITA of MSEK 1,186 on sales of around BSEK 7.9, with an EBITA margin of 15.0%.

The Vinge team consists of partner Erik Gabrielson together with associate Mattias Sköld and, inter alia, Mathias Lindquist, Ida Christensson, Kristoffer Franzkeit and Hampus Wikerstål.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024